RP-3500 (Synonyms: RP-3500; ATR inhibitor 4) |
Catalog No.GC64278 |
Le RP-3500 (inhibiteur d'ATR 4) est un inhibiteur sélectif de l'ATR kinase (ATRi) actif par voie orale avec une IC50 de 1,00 nM dans les tests biochimiques. Le RP-3500 présente une sélectivité de 30 fois pour l'ATR sur mTOR (IC50 = 120 nM) et une sélectivité > 2 000 fois sur les kinases ATM, DNA-PK et PI3Kα. Le RP-3500 a une puissante activité antitumorale.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2417489-10-0
Sample solution is provided at 25 µL, 10mM.
RP-3500 (ATR inhibitor 4) is an orally active, selective ATR kinase inhibitor (ATRi) with an IC50 of 1.00 nM in biochemical assays. RP-3500 shows 30-fold selectivity for ATR over mTOR (IC50=120 nM) and >2,000-fold selectivity over ATM, DNA-PK, and PI3Kα kinases. RP-3500 has potent antitumor activity[1].
RP-3500 (ATR inhibitor 4; 1 μM; 1-24 hours) inhibits CHK1(Ser345) phosphorylation from 1 to 3 hours[1]. RP-3500 inhibits Gemcitabine stimulated ATR phosphorylation of its substrate pCHK1(Ser345) with an IC50 of 0.33 nM in a LoVo cell-based assay[1].
RP-3500 (ATR inhibitor 4; 3, 7, 15 mg/kg; Orally; once daily for 18 days) produces dose-dependent tumor growth inhibition with a minimum effective dose (MED) of 7 mg/kg in LoVo xenografts[1]. RP-3500 (5, 10 mg/kg; Orally; once daily) produces statistically significant tumor growth inhibition in the CW-2 colon xenograft model[1]. RP-3500 (7 mg/kg; for 7 days) results in 8.1- and 2.7-fold inductions of KAP1 and DNA-PKcs phosphorylation in mice bearing LoVo tumors[1]. RP-3500 has a more profound anti-tumor effect occurred at higher doses on the 3 days on/4 days off (30 mg/kg) and 5 days on/2 days off (25 mg/kg) schedules compared with consecutive daily administrations (10 mg/kg) at a lower dose for 14 days[1]. RP-3500 (15mg/kg) combined PARPi Olaparib (80mg/kg; both agents days 1-3 on/4 days off) or sequential (PARPi for 3 days followed by RP-3500 for 3 days then 1 day off) schedules produces greater antiTumor effects compared with sequential administration without affecting tolerability[1].
[1]. Anne Roulston, et al. RP-3500: A Novel, Potent and Selective ATR Inhibitor that is Effective in Preclinical Models as a Monotherapy and in Combination with PARP Inhibitors. Mol Cancer Ther
Average Rating: 5
(Based on Reviews and 24 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *